The region regulated by the European Medicines Agency (EMA) has been the most proactive globally in the early adoption of biosimilars. By February 2023, it had approved around 75 products containing them. The distribution of such compounds within Europe, however, has been uneven, with some countries offering more market opportunities than others. Beyond Europe, few producers have a strategy for the Middle East and/or Africa, and India and South Korea could soon jump in to fill the gap.
Membrane Proteins
Sponsored PublicationsTransmembrane proteins play a variety of roles in physiological processes such as protein ligation, recognition, transport, anchoring, and transduction.
Glioma drug combo turns tumours hot
Latest NewsAn anti-TNF-antibody-cytokine fusion combo with chemotherapy turns inoperable brain tumours hot in mice. A Phase I trial sponsored by Philogen SpA is underway.
Life Science ecosystem Rhine Neckar: Hot spot for investors
BackgroundThe BioRN Life Science cluster Rhine-Neckar has set the right course to further accelerate the start-up dynamic. Several lighthouse projects have been established recently, fostering innovation and providing the ideal breeding ground for biotech projects. Joint forces now develop strategies to attract investors and increase the visibility of the start-up community. The Life Science Investors´ Day Heidelberg has established itself as a top-class platform.
VectivBio taken over in $1bn acquisition
Latest NewsGI specialist Ironwood Pharmaceuticals Inc. has announced to acquire Swiss VectivBio Holding AG for $17 per share in an all-cash transaction.
Does science really always win?
Background2. BIOTECH CIRCLE – Almost twice as many visitors as at last year’s premiere were welcomed by Biotech Austria’s Chairman Peter Llewellyn-Davies in the Vienna Stock Exchange in April. Framed by a Flying Breakfast, the topic was the provocative question Science always wins?!
AI predicts an enzyme’s substrate
Latest NewsA new machine learning model can predict enzyme-substrate pairs, with an accuracy of over 90% and is ready to be used in pharmaceutical and industrial biotechnology.
Building on the successes of Europe’s bioeconomy
OpinionThe bioeconomy can be a major driver in bringing circularity, sustainability and competitive production to Europe as it aims towards becoming climate-neutral and more self-sufficient.
LanzaTech and Plastipak produce greener PET
Latest NewsCarbon-capture specialist LanzaTech Global and Plastipak Packaging Inc have produced the world’s first PET resin made from captured carbon emissions.
Roche’s meets endpoints in relapsing multiple sclerosis
Latest NewsRoche’s bruton’s tyrosine kinas blocker fenebrutinib has met all endpoints in proof-of-concept study with patients suffering from relapsing-remitting multiple sclerosis.
How to build on Europe’s strengths
BackgroundThe region regulated by the European Medicines Agency (EMA) has been the most proactive globally in the early adoption of biosimilars. By February 2023, it had approved around 75 products containing them. The distribution of such compounds within Europe, however, has been uneven, with some countries offering more market opportunities than others. Beyond Europe, few producers have a strategy for the Middle East and/or Africa, and India and South Korea could soon jump in to fill the gap.